{"filing":{"accession_number":"0001628280-26-061978","cik":"0001232524","ticker":"JAZZ","company_name":"Jazz Pharmaceuticals plc","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-15","primary_document":"jazz-20260915.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1232524/000162828026061978/jazz-20260915.htm"},"events":[{"id":33530,"run_id":30832,"accession_number":"0001628280-26-061978","anchor_item_number":"7.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"Jazz Pharmaceuticals announced the completion of its acquisition of Actio Biosciences for $820 million upfront, with Actio becoming a wholly-owned subsidiary. The press release explicitly states \"Jazz completed the acquisition of Actio Biosciences through the merger of Knight Acquisition Corp...with and into Actio,\" which is a material acquisition transaction. This is a completed M\u0026A activity that would materially affect investor assessment of the registrant's strategic position and financial obligations.","company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":[{"id":36997,"accession_number":"0001628280-26-061978","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Jazz Pharmaceuticals announced the completion of its acquisition of Actio Biosciences for $820 million upfront, with Actio becoming a wholly-owned subsidiary. The press release explicitly states \"Jazz completed the acquisition of Actio Biosciences through the merger of Knight Acquisition Corp...with and into Actio,\" which is a material acquisition transaction. This is a completed M\u0026A activity that would materially affect investor assessment of the registrant's strategic position and financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T13:07:38.261051+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36997,"accession_number":"0001628280-26-061978","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Jazz Pharmaceuticals announced the completion of its acquisition of Actio Biosciences for $820 million upfront, with Actio becoming a wholly-owned subsidiary. The press release explicitly states \"Jazz completed the acquisition of Actio Biosciences through the merger of Knight Acquisition Corp...with and into Actio,\" which is a material acquisition transaction. This is a completed M\u0026A activity that would materially affect investor assessment of the registrant's strategic position and financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T13:07:38.261051+00:00","company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","filing_date":"2026-09-15"}]}